annb0t
Top 20
Immutep Limited
Media Release
Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC) Compelling Phase II results in 1L NSCLC, including Overall Response Rate (ORR) of 40.4% in all-comer
PD-L1 TACTI (Two ACTive Immunotherapies trial)-002 trial combining efti and pembrolizumab, showcased at SITC 2022 press briefing Successful meeting with FDA for efti in metastatic breast cancer (MBC) ...
>>> Read more: Immutep Quarterly Activities Report
Media Release
Second US FDA Fast Track designation granted to eftilagimod alpha (efti) supporting planned late-stage development in 1st line non-small cell lung cancer (1L NSCLC) Compelling Phase II results in 1L NSCLC, including Overall Response Rate (ORR) of 40.4% in all-comer
PD-L1 TACTI (Two ACTive Immunotherapies trial)-002 trial combining efti and pembrolizumab, showcased at SITC 2022 press briefing Successful meeting with FDA for efti in metastatic breast cancer (MBC) ...
>>> Read more: Immutep Quarterly Activities Report
